Elspar
(Asparaginase)Phase 3Protein / enzyme
Asparaginase is used to treat certain types of leukemia and lymphoma by blocking a nutrient that cancer cells need to survive and grow.[1] Elspar is currently being investigated across 8 indications[3], with its most advanced program in Phase 3.[1]
Elspar is one of 175 small molecule programs targeting Acute Myeloid Leukemia. It is currently in Phase 3.
8
Indications
87
Total Trials
13
Active Trials
174
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
255 competitors in Acute Myeloid Leukemia
#DrugCompanyPhaseTrials
1Novantrone
PfizerPhase 3
Xospata
AstellasPhase 3
Fludara
SanofiPhase 3
Cerubidine
EEastern Cooperative Oncology Group
Phase 3
Vepesid
AAvyxa
Phase 3
Mylotarg
WWyeth-Lederle Vaccines
Phase 3
Vanflyta
Daiichi SankyoPhase 3
Neupogen
EEastern Cooperative Oncology Group
Phase 3
Nexavar
BayerPhase 3
Cellcept
RochePhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Acute Lymphoblastic Leukemia45 trials
Show 42 more trials
A Study in Adults With Untreated Acute Lymphoblastic Leukemia
Completed·—·Phase 2·NCT00136435·100 enrolled
Asparaginase Erwinia Chrysanthemi With Chemotherapy for the Treatment of High-Risk Adults With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
Recruiting·—·Phase 2·NCT06918431·53 enrolled
Risk-Adjusted Combination Chemotherapy in Treating Young Patients With Acute Lymphoblastic Leukemia
Unknown status·—·Phase 3·NCT00764907·4,000 enrolled
PO Ixazomib in Combination With Chemotherapy for Childhood Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma
Active, not recruiting·TTherapeutic Advances in Childhood Leukemia Consortium·Phase 1/2·NCT03817320·24 enrolled
Treatment of Acute Lymphoblastic Leukemia in Children
Completed·—·Phase 3·NCT00165178·498 enrolled
Leukemia7 trials
Show 4 more trials
Acute Myeloid Leukemia7 trials
Bone Marrow Transplantation3 trials
Lymphoblastic Lymphoma3 trials
16 more indications
Lymphoma3 trials
Recurrent B Acute Lymphoblastic Leukemia3 trials
Acute Lymphoblastic Leukaemia2 trials
The Association Between Asparaginase Enzyme Activity Levels and Toxicities in Childhood Acute Lymphoblastic Leukaemia in NOPHOALL 2008
Completed·—··NCT04187248·1,248 enrolled
Myelodysplastic Syndromes2 trials
Nasopharyngeal Carcinoma1 trial
Compassionate Use of Asparaginase and Pembrolizumab Combination Theaapy for Nasopharyngeal Carcinoma
Completed·—·N/A·NCT06676293·8 enrolled
Hypersensitivity1 trial
Allergy1 trial
Myeloproliferative Disorder1 trial
B-cell acute lymphoblastic leukemia1 trial
Childhood Acute Lymphoblastic Leukemia1 trial
Treatment of Childhood Acute Lymphoblastic Leukemia
Terminated·—·Phase 3·NCT00165087·491 enrolled
B Acute Lymphoblastic Leukemia1 trial
B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Asparaginase. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Protein / enzyme[2]
- Highest Phase
- Phase 3[1]
- Company
- DDutch Childhood Oncology Group